Savara ($SVRA) Concealed BLA Risks and Capital Shortfall Case

The court has appointed the lead plaintiff to represent the class.

E.D. Pennsylvania

Court

2:25-cv-05147

Case number

03/07/2024

Class period Start

05/23/2025

Class period End

11/10/2025

Lead Plaintiff motion deadline

$SVRA investors filed a claim against Savara for misrepresenting the completeness of its Biologics License Application (BLA) and misleading investors about regulatory timelines and capital needs.
After the FDA rejected Savara’s BLA for MOLBREEVI due to missing manufacturing data, $SVRA fell 31.7% on May 27, 2025.
$SVRA investors can join this case to be notified about potential recovery.
Case Details:

Between March 7, 2024, and May 23, 2025, Savara repeatedly assured investors it was on track to submit and complete a high-quality BLA for its lead product, MOLBREEVI, a therapy for autoimmune pulmonary alveolar proteinosis (aPAP). Executives stated the company was well-capitalized through 2026–2027 and projected a potential FDA approval by year-end 2025.

Savara claimed it had completed its rolling BLA submission in March 2025 and had requested Priority Review. However, the company failed to disclose that the BLA lacked key Chemistry, Manufacturing, and Controls (CMC) data required for FDA review. Despite knowing the regulatory risk, the company continued to provide overly optimistic timelines and reassured investors that submission was complete and under review.

On May 27, 2025, Savara revealed it had received a Refusal to File (RTF) letter from the FDA, which found the BLA "not sufficiently complete" for review due to missing CMC data. Analysts immediately flagged delays in commercialization, potential manufacturing strategy changes, and the need for further capital raises. $SVRA fell 31.7%.

Then, in August 2025, Savara confirmed it would resubmit the BLA in December 2025, missing its original Q1 target and delaying any potential approval or market launch until at least 2026–2027.

Based on these events, $SVRA investors filed a claim against Savara, alleging the company:
It misrepresented the completeness and quality of its BLA submission to the FDA.
It concealed deficiencies in CMC data and regulatory readiness for MOLBREEVI.
It misled investors about its projected approval timeline and capital sufficiency.
Investors argue Savara misled the market about its regulatory preparedness and financial outlook, exposing shareholders to losses when the FDA rejected the filing.

Case Type

US Securities Class Action

Case Status

Lead Plaintiff Appointed

Alleged Offence

Misleading Statements,

Financial Misrepresentation,

Failure to Disclose

Suspected Party

Management

Security Type

Stocks

Trade Direction

Long

Shock Event Date

05/27/2025

Filing date

09/08/2025

Lead Plaintiff Deadline

11/10/2025

Trusted by industry leaders

Endorsed by top professionals who trust our innovative solutions to drive impactful results.